KRAS and metastatic colorectal cancer: This study showed that adagrasib, an inhibitor of the mutant KRAS G12C protein, had antitumor activity in heavily pretreated metastatic colorectal cancer patients, both as a monotherapy and in combination with cetuximab [49].